May 9,China Resources ShuangheAt the opening daily limit, the stock price was reported at 30.16 yuan per share, with nearly 700,000 orders.
On the news, the company yesterday eveningannouncementsigned the “Strategic Cooperation Agreement” and the “Framework Agreement for the Entrusted Processing and Production of Azvudine Tablets” with Real Bio, and was entrusted with the processing and production of real bio new crown oral drug Azvudine products.China Resources ShuangheAt present, it has submitted an application for the issuance of a drug production license C to the Beijing Municipal Food and Drug Administration and has been approved. It has the production capacity and quality assurance ability of the entrusted processing of the product.The two parties will carry out clinical trials and approve the market application of Azvudine tablets according to the actual situation of each stage, but will separately sign a commission for specific matters such as order plan, settlement method, delivery time and quality requirements involved in the commissioned processing and production.contract。
Previously,China Resources ShuangheThe market news about the cooperation with Real Bio on the new crown oral drug has been fermenting for a long time. The company’s stock price has fluctuated upwards since the lowest point of the year on March 16, and has risen by more than 158% in the past 34 trading days.
(Article source: ChinasecuritiesReport · China Securities Network)
Article source: China Securities Journal China Securities Network
Responsible editor: 436
Original title: Entrusted to process and produce real biological new crown oral drug Azvudine tablets China Resources Shuanghe daily limit
Solemnly declare: Oriental Fortune.com releases this information for the purpose of disseminating more information and has nothing to do with the position of this site.